Objective To evaluate the efficacy and adverse reactions of different blue phototherapy modes on neonatal hyperbilirubinemia,in order to provide scientific evidence for clinical treatment. Methods The clinical randomized controlled study on the treatment of neonatal hyperbilirubinemia by blue phototherapy published from the database inception to May 2018,were retrieved in PubMed,EMBASE,Web of science,Cochrane library,CNKI,VIP and WanFang database. Most literature results were analyzed by RevMan 5.3,but some results were dealt by other medical statistics methods. Results Finally 8 literature containing 954 patients were selected. Meta-analysis showed that phototherapy can significantly decrease the infants′ serum bilirubin level (SMD=55.35,95%CI:50.23-60.48, P<0.001),of which both intermittent phototherapy and continuous phototherapy can also decrease the infants′ serum bilirubin concentration (SMD=58.72,95%CI:54.35～63.09, P<0.001;SMD=51.53,95%CI:41.48～ 61.59, P<0.001). However,the differences on cure rate of neonatal hyperbilirubinemia (χ2=0.00,P=1.00) and the decrease value of the serum bilirubin concentration (SMD=-1.24,95%CI:-5.62-3.15,P=0.58) between different blue phototherapy modes were not significant. Compared with continuous phototherapy,intermittent phototherapy showed lower rate of adverse reactions (RR=0.18,95%CI :0.13-0.25,P<0.001). Conclusions Both intermittent phototherapy and continuous phototherapy can effectively decrease the infants′ serum bilirubin concentration. Meanwhile,the intermittent phototherapy can better reduce the incidence of adverse reactions than continuous phototherapy.
Key words
blue phototherapy /
bilirubin /
adverse reaction /
Meta-analysis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Hansen TWR.Phototherapy for neonatal jaundice-therape utic effects on more than one level?[J].Semin Perinatol,2010,34(3):231-234.
[2] Kaplan M,Wong RJ,Sibley E.Neonatal jaundice and liver disease[J].Elsevier,2011,20(4):1443-1496.
[3] Scheidt PC,Bryla DA,Nelson KB,et al.Phototherapy for neonatal hyperbilirubinemia:six-year follow-up of the national institute of child health and human development clinical trial[J].Pediatrics,1990,85(4):455-463.
[4] Wickremasinghe AC,Kuzniewicz MW,Grimes BA,et al.Neonatal phototherapy and infantile cancer[J].Pediatrics,2016,137(6):1353-1353.
[5] Amos RC,Jacob H,Leith W,et al.Jaundice in newborn babies under 28 days:NICE guideline 2016 (CG98)[J].Arch Dis Child Educ Pract Ed,2017,102(4):207-209.
[6] Niknafs P,Mortazavi AA,Torabinejad MH,et al.Intermittent versus continuous phototherapy for reducing neonatal hyperbilirubinemia[J].Iranian Journal of Pediatrics,2008,18(3):251-256.
[7] Sachdeva M,Murki S,Oleti TP,et al.Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age:a randomized controlled trial[J].Eur J Pediatr,2015,174(2):177-181.
[8] Khaliq A.Comparison of continuous with intermittent phototherapy in the treatment of neonatal jaundice[J].JPMI,2016,30(2):1810-1812.
[9] 张亦维.两种光疗方法治疗175例新生儿高未结合胆红素血症的疗效观察[J].重庆医学,2009,38(6):706-706.
[10] 唐红装,梁丽清,谢映梅.短时多次蓝光疗法在新生儿黄疸治疗中的效果观察与护理[J].广东医学,2010,31(23):3154-3155.
[11] 华旭丹.不同方法蓝光照射治疗新生儿高胆红素血症的疗效[J].中国妇幼保健,2012,27(17):2715-2716.
[12] 李罡.间歇性蓝光照射辅助治疗新生儿黄疸临床分析[J].中国妇幼保健,2013,28(23):3777-3779.
[13] 杨春鸿,金晓秋.蓝光间歇辅助治疗新生儿黄疸效果观察[J].中国妇幼保健,2013,28(23):3799-3800.
[14] Maisels MJ,Kring E.The contribution of hemolysis to early jaundice in normal newborns[J].Pediatrics,2006,118(1):276-279.
[15] Burke BL,Robbins JM,Bird TM,et al.,Trends in hospitalizations for neonatal jaundice and kernicterus in the United States,1988-2005[J].Pediatrics,2009,123(2):524-532.
[16] Kuzniewicz MW,Escobar GJ,Newman TB.Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use[J].Pediatrics,2009,124(4):1031-1039.
[17] Maisels MJ,McDonagh AF.Phototherapy for neonatal ja undice[J].N Engl J Med,2008,358(9):920-928.
[18] Podvin D,Kuehn CM,Mueller BA,et al.Maternal and birth characteristics in relation to childhood leukaemia[J].Paediatr Perinat Epidemiol,2006,20(4):312-322.
[19] Cnattingius S,Zack M,Ekbom A,et al.Prenatal and neonatal risk factors for childhood myeloid leukemia[J].Cancer Epidemiol Biomarkers Prev,1995,4(5):441-445.
[20] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia.Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J].Pediatrics,2004,114(1):297-316.
PDF(1538 KB)
